Integrative Cancer Therapies

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burzynski, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burzynski, S. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Integrative Cancer Therapies, Vol. 3, No. 1, 47-58 (2004)
DOI: 10.1177/1534735403261964

The Present State of Antineoplaston Research (1)

Stanislaw R. Burzynski

Burzynski Research Institute, Houston, TX, info{at}burzynskiclinic.com

Antineoplastons work as molecular switches, which regulate expression of genes p53 and p21 through demethylation of promoter sequences and acetylation of histones. They also inhibit the uptake of growth-critical amino acids, such as 1- glutamine and 1-leucine in neoplastic cells. Phase II trials indicate efficacy of antineoplastons in low-grade glioma, brain stem glioma, high-grade glioma, adenocarcinoma of the colon, and hepatocellular carcinoma. The best results were observed in children with low-grade glioma, where 74% of patients obtained objective response, and in patients with adenocarcinoma of the colon with liver metastases whose survival rate of more than 5 years is 91% versus 39% in controls on chemotherapy. Gene array studies will explain antineoplaston-induced changes in gene expression.

Key Words: antineoplastons • brain tumors • gliomas • colon cancer • liver cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
A. Munshi, L. H. Ni, and M. S. Tiwana
Complementary and Alternative Medicine in Present Day Oncology Care: Promises and Pitfalls
Jpn. J. Clin. Oncol., August 5, 2008; (2008) hyn066v1.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
S. R. Burzynski, T. J. Janicki, R. A. Weaver, and B. Burzynski
Targeted Therapy With Antineoplastons A10 and AS2-1 of High-Grade, Recurrent, and Progressive Brainstem Glioma.
Integr Cancer Ther, March 1, 2006; 5(1): 40 - 47.
[Abstract] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. S. Kirschner
Emerging Treatment Strategies for Adrenocortical Carcinoma: A New Hope
J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 14 - 21.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
S. R. Burzynski, R. A. Weaver, T. Janicki, B. Szymkowski, G. Jurida, M. Khan, and V. Dolgopolov
Long-term Survival of High-Risk Pediatric Patients With Primitive Neuroectodermal Tumors Treated With Antineoplastons A10 and AS2-1
Integr Cancer Ther, June 1, 2005; 4(2): 168 - 177.
[Abstract] [PDF]

Home page
 Integr Cancer TherHome page
A. Vickers
Letter to the Editor
Integr Cancer Ther, September 1, 2004; 3(3): 199 - 199.
[PDF]

Home page
 Integr Cancer TherHome page
S. R. Burzynski
Letter to the Editor
Integr Cancer Ther, September 1, 2004; 3(3): 200 - 200.
[PDF]